Redeye: Xvivo Perfusion - Harvest Season is Coming

We have conducted a survey to transplant physicians I the United States and Europe. Results indicate a high potential for warm perfusion. In light of the survey results and a deeper analysis of the newly formed collaboration with United Therapeutics, we forecast a slightly faster adaption of warm perfusion than previously accounted for. Our new fair value (base case) is SEK 160 (110) per share.

Read more and download the research update: 

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.